

BACKGROUND

- 2004 – 2019 **Therapist, speaker and lecturer on Sciences and complementary and alternative medicines (CAM) (hypnosis, DNA, conscious and science, independent researcher on CAM)**
- 2000 - 2014 **Self-employed medical and scientific writer (BioSuccess),**
- 1998 – 2000 **Post-doctorate in Neuro-immunology – Urbana Champaign - USA**
- 1995 – 1998 **Post-doctorate in Neuro-immunology – National Institute of Health and Medical Research (INSERM) - Bordeaux - France**
- 1992 - 1995 **PhD. in Neurosciences and Pharmacology –Sanofi - France**
- 1989 **Postgraduate Diploma in Immunology – Pasteur Institute – Paris - France**
- 1986 **Medical Degree in Immunology - Toulouse –France.**
- 1985 **Master's in Biochemistry and Molecular biology - Toulouse - France**

PROFESSIONAL EXPERIENCES

Participation in European “Framework Program 7” (FP7) (2011 – 2012)

- FP-7 – SME 2013 – Research for the benefit of SMEs – “Selpatch”: a transdermal Selegiline patch for treating treatment resistant depression
Coordinator: Andrew Gardiner, Syntropharma (U.K.)
Workpackage leader in dissemination: F. Pousset
- FP-7 – Health 2012” – INNOVATION-1: Small scale SME collaborative project – “AndroCan”
Coordinator: Foch Hospital (France)
Workpackage leader in dissemination: F. Pousset
- FP-7 – Health 2012” – INNOVATION-1: Large scale collaborative project “Trust-eP2C” –
Coordinator: “Commissariat à l’Energie Atomique” (France)
Workpackage leader in dissemination: F. Pousset

Scientific consultant

- Agrofood/Dietary supplement companies: Oronalia (Luxembourg), Danone Research Center (Paris, France – Barcelonna, Spain), Fortepharma (Monaco), Boiron (France), Nutergia (France), Rosebud SA (Suisse)
- Pharmaceutical companies: Pierre Fabre Medicament (France), Pierre Fabre Research Institute in Dermatology (France), L’Oréal (France), Servier (France), Johnsson & Johnsson (France), Pharmatoka (France), Joint Pharma Research (U.K.), Orfagen (France), Celectis (France), Grey Healthcare (France), RDW Pharma (France), Ceva Animal (France)
- Public Institutes: Foch Hospital (France), Bergonié Institute of Cancerology (France), Public Health Foundation (France), Bordeaux University (Department of Pharmacology)
- Associations: Mediterranean Association of Phytotherapy and Medicinal Plants (France), Association of Rare Diseases (France), Rare Disease Alliance (France)
- Contact Research Organizations: Axonal (France) – Cardinal system (France)

Private company employment

- Rosebud SA company – Switzerland- Co-inventor and associate (2008-2015)
- Sanofi – France - Department of Neuropsychiatry - PhD in Neuroscience and Pharmacology (1992-1995)
- Sanofi – France - Department of Molecular Biology of the gene - Scientific Assistant (1988-1989)
- Sanofi – France - Department of Neuropsychiatry - Technical Assistant (1988)

Public Institutions

National Institute of Health and Medical Research (INSERM) - Integrative Neurobiology – Bordeaux II University - France - Post-doctorate in neuro-immunology (1998-2000)

University of Urbana – USA - Post-doctorate in neuro-immunology (1995-1998)

National Center for Scientific Research (CNRS) – Immunology - Purpan Hospital – France (1988-1989)

DOMAINS OF EXPERTISE

Scientific and medical qualifications

Neurobiology, Neuropsychiatry, Immunology, Neuro-immunology, Oncology, Urology, Nutrition

Alternative and complementary medicines

Bioelectrophotonic (GDV), Homeopathy, oligotherapy, gemmotherapy, kinesiology, dietary supplementation, phytotherapy, magnetism, quantum energy, Future Life Progression

INTERNATIONAL EXPERT

Member of the Scientific Advisory Board of Vitafoods 2013-2014

Associate of Rosebud S.A. (Switzerland)

- * Development of a range of dietary supplements from idea to market (since 2007)
- * Commercialization of the first product “SHS Synbiotic” in 2012
- * Development of SHS portfolio

International Expert for the “Consejeria de Educacion” Spain

- * Consejeria de Education project grant application 2000
- * Consejeria de Education project grant application 2000

“Medical Research Council” United kingdom

- * MRC Project grant application 1995
- * MRC Clinical Training Fellowships 1996
- * MRC Career Development award 1996

PATENTS

EP2233015/WO2010079444 published in 2010, co-inventors F. Pousset and B. Allemand
"Synbiotic composition and method for the manufacture thereof"

2401925 published in 2014, co-inventors F. Pousset and B. Allemand
"Prebiotic product and manufacturing method"

COLLABORATIONS

2014 – 2018

- **Future Life Institute – John Mee - USA**
- **Independent research on modified state of consciousness** based on a new hypnosis method and DNA reprogramming

2002-2014

- * Scientific and medical writer for companies and national institutes :
- **eCTD registration, European Call for proposal, Literature review, Scientific and medical information survey, Scientific dossier, Monography, Clinical study protocol, Publication, Investigational brochure, Technical documentation, Health claim dossier, Note of therapeutic interest, Medico-Marketing leaflet, Meeting report, Scientific and medical information survey, Expert report**

PUBLICATIONS (Peer-reviewed international journals)

1. Parnet P, **Pousset F.**, Laye S. NF kappa B activation in mouse pituitary: comparison of response to interleukin-1 beta and lipopolysaccharide. (2003) *J Neuroendocrinol.* Mar;15(3):304-14.
2. **Pousset F.**, Cremona S., Dantzer R., Kelley K. and Parnet P. (2001) Dexamethasone up-regulates type II IL-1 receptor in mouse primary activated astrocytes. *Journal of Neurochemistry*, 76: 901-909
3. Palin K., **Pousset F.**, Verrier D., Dantzer R., Kelley K., Parnet P. and Lestage J. (2001) Characterization of Interleukin-1 receptor antagonist isoform expression in the brain of lipopolysaccharide-treated rats. *Neuroscience*, 103: 161-169.
4. **Pousset F.**, Cremona S., Dantzer R., Kelley K. and Parnet P. (2001) IL-4 and IL-10 regulate type I and type I interleukin-1 receptor expression on IL-1 β - activated mouse primary astrocytes. *Journal of Neurochemistry*.
5. Parnet P., **Pousset F.** and Layé S. (2001) Differential pattern of NFkB activation in mouse pituitary following systemic administration of IL-1 and LPS.
6. **Pousset F.**, Palin K., Verrier D., Bristow A., Dantzer R., Parnet P. and Lestage J. (2000) Production of interleukin-1 receptor antagonist isoforms by microglia in mixed rat glial cells stimulates by lipopolysaccharide. *European Cytokine Network*, 11: 682-689.
7. **Pousset F.**, Dantzer R., Kelley K. and Parnet P. (2000) Interleukin-1 signaling in mouse astrocytes involves Akt: a study with interleukin-4 and interleukin-10. *European Cytokine Network*, 11: 427-434.
8. Bluthé R-M, Castanon N., **Pousset F.**, Bristow A., Ball C., Lestage J., Michaud B., Kelley K. and Dantzer R. (1999) Central injection of IL-10 antagonizes the behavioral effects of lipopolysaccharide in rats. *Psychoneuroendocrinology*. 24 : 301-311.
9. **Pousset F.**, Cremona S., Dantzer R., Kelley K. and Parnet P. (1999) Interleukin-4 and interleukin-10 regulate IL-1 β induced mouse primary astrocytes activation : a comparative study. *Glia*. 2 : 12-21.
10. **Pousset F.**, Fournier J., Legoux P. , Keane P., Shire D. and Soubrié P. (1996) Effect of serotonin on cytokine mRNA expression in rat hippocampal astrocytes. *Molecular Brain Research*. 38 : 54-56.
11. **Pousset F.** (1994) Developmental expression of cytokine genes expression in the cortex and hippocampus of the rat central nervous system. *Developmental Brain Research* 81 : 143-146.

REVIEW

1. Petry K., Boullerne A., **Pousset F.**, Brochet B., Caillé J-M. and Dousset V. (2000) Experimental allergic encephalomyelitis animals models for analyzing features of Multiple Sclerosis. Pathologic Biologic. *Pathologie Biologie*. 48: 47-53.
2. **Pousset F.** (1994) Review : Cytokines as mediators of the central nervous system. *Biomedecine and Pharmacotherapy* 48 : 425-431.
3. **Pousset F.** (1993) Cytokines in the brain 1992. *European Cytokine Network* 4 : 57-61.

BOOK CHAPTER

1. **Pousset F.**, Fournier J. and Keane P. (1997) Expression of cytokine genes during ontogenesis of the central nervous system. *Ann. N.Y. Acad.Sci.* 814: 97-108.
2. Dantzer R., Bluthé R-M, Castanon N., Chauvet N., Capuron L., Goodall G., Kelley K., Konsman J-P, Layé S., Parnet P. and **Pousset F.** (1999) Cytokine effects on behavior. *Psychoneuroimmunology*, R. Ader, Felten D. and Cohen N. 3rd edition, Academic Press